Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltest

    Final published version, 1.98 MB, PDF document

  • the INSIGHT START study group

Understanding of pandemics depends on the characterization of pathogen collections from well-defined and demographically diverse cohorts. Since its emergence in Congo almost a century ago, Human Immunodeficiency Virus Type 1 (HIV-1) has geographically spread and genetically diversified into distinct viral subtypes. Phylogenetic analysis can be used to reconstruct the ancestry of the virus to better understand the origin and distribution of subtypes. We sequenced two 3.6-kb amplicons of HIV-1 genomes from 3,197 participants in a clinical trial with consistent and uniform sampling at sites across 35 countries and analyzed our data with another 2,632 genomes that comprehensively reflect the HIV-1 genetic diversity. We used maximum likelihood phylogenetic analysis coupled with geographical information to infer the state of ancestors. The majority of our sequenced genomes (n = 2,501) were either pure subtypes (A–D, F, and G) or CRF01_AE. The diversity and distribution of subtypes across geographical regions differed; USA showed the most homogenous subtype population, whereas African samples were most diverse. We delineated transmission of the four most prevalent subtypes in our dataset (A, B, C, and CRF01_AE), and our results suggest both continuous and frequent transmission of HIV-1 over country borders, as well as single transmission events being the seed of endemic population expansions. Overall, we show that coupling of genetic and geographical information of HIV-1 can be used to understand the origin and spread of pandemic pathogens.

Original languageEnglish
Article numberA1347
JournalVirus Evolution
Volume7
Issue number2
DOIs
Publication statusPublished - 2021

Bibliographical note

Funding Information:
The primary funder of the START trial was NIAID (grant numbers UM1-AI068641, UM1-AI120197, and 1U01-AI136780). This study was made possible through a grant from the Danish National Research Foundation (grant number 126). Additional support was obtained from the National Institute of Allergy and Infectious Diseases, National Institutes of Health Clinical Center, National Cancer Institute, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Agence Nationale de Recherches sur le SIDA et les H?patites Virales (France), National Health and Medical Research Council (Australia), Bundesministerium f?r Bildung und Forschung (Germany), European AIDS Treatment Network, Medical Research Council (United Kingdom), National Institute for Health Research, National Health Service (United Kingdom), and University of Minnesota. Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck. M.W. was supported by NIH/NIAID R01AI084691.

Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press.

    Research areas

  • Ancestral State Reconstruction, HIV, Phylogenetics, Phylogeography, Transmission

ID: 303774429